PD-1 antibody (Programmed Cell Death 1)

Details for Product anti-PDCD1 Antibody No. ABIN6730992
Antigen
Reactivity
Human
355
143
49
5
3
1
Host
CHO Cells
189
163
36
24
17
11
5
4
1
Antibody Type
Recombinant Antibody
Clonality (Clone)
Monoclonal ()
Conjugate
This PD-1 antibody is un-conjugated
27
21
20
10
7
6
5
4
4
4
4
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
Application
Blocking Reagent (BR), ELISA, Flow Cytometry (FACS), Immunoprecipitation (IP), Western Blotting (WB)
235
173
119
101
90
71
21
15
13
12
12
11
10
10
9
4
4
2
2
2
Options
Purpose Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody (HuMAb), which binds to the programmed death-1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2.
Clone Nivolumab (5C4-B8)
Specificity "Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody (HuMAb), which binds to the programmed death-1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2."
Characteristics "This is a therapeutic antibody derived from Opdivo and designed for research purposes. Nivolumab, the active ingredient of Opdivo, is a human immunoglobulin G4 (IgG4) monoclonal antibody (HuMAb), which binds to the programmed death-1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2."
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody (HuMAb), which binds to the programmed death-1 (PD-1) receptor and blocks its interaction with PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. Engagement of PD-1 with the ligands PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment, results in inhibition of T-cell proliferation and cytokine secretion. Nivolumab potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2 ligands. In syngeneic mouse models, blocking PD-1 activity resulted in decreased tumour growth.
Combined nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) mediated inhibition results in improved anti-tumour responses in metastatic melanoma. In murine syngeneic tumour models, dual blockade of PD-1 and CTLA-4 resulted in synergistic anti-tumour activity.
Purification The commercial therapeutic mAb was diluted with sterile PBS to a final 1 mg/ml.  (original drug Opdivo 100 was diluted 1:10)
Sterility Sterile
Antigen
Alternative Name PD-1 (PDCD1 Antibody Abstract)
Background Synonyms: CD279, PD1, SLEB2, hPD-1, hPD-l, Ly101, Pdc1
Molecular Weight 32 kDa
Gene ID 5133
UniProt F5A532
Pathways Cancer Immune Checkpoints
Application Notes Optimal dilution for a specific application should be determined by user
Comment

Nivolumab is produced in Chinese hamster ovary cells by recombinant DNA technology

Protocol Research-relevant quantities are available as licence-free consumable as diluted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments.
Restrictions For Research Use only
Format Liquid
Concentration 1 mg/mL
Buffer The dilutant is sterile PBS pH 7.4. No preservatives added
Preservative Without preservative
Handling Advice open only under sterile conditions
Storage 4 °C,-20 °C
Storage Comment Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
Expiry Date 24 months